By Ian Walker

AstraZeneca PLC (AZN.LN) said Tuesday that Farxiga met the primary endpoint in a Phase 3 trial for the treatment of patients with heart failure.

The pharmaceutical giant said Farxiga significantly reduced the risk of cardiovascular death or worsening of heart failure when added to standard of care.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

August 20, 2019 02:25 ET (06:25 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca